Advertisement
Screener

CalciMedica, Inc. (CALC) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.7 / 5 stars · 9/26 Roast Me

CalciMedica, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

CalciMedica, Inc. (CALC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-11

  • CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-06-300.00%
10-Q · filed 2026-08-11
2026-03-310.00%
10-Q · filed 2026-05-12
2025-12-310.00%
10-K · filed 2026-03-03
2025-09-300.00%
10-Q · filed 2025-11-12
2025-06-300.00%
10-Q · filed 2026-08-11
2025-03-310.00%
10-Q · filed 2026-05-12
2024-12-310.00%
10-K · filed 2026-03-03
2024-09-300.00%
10-Q · filed 2025-11-12
2024-06-300.00%
10-Q · filed 2025-08-12
2024-03-310.00%
10-Q · filed 2025-05-14
2023-12-310.00%
10-K · filed 2025-03-27
2023-09-300.00%
10-Q · filed 2024-11-13
2023-06-300.00%
10-Q · filed 2024-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
TALPHERA, INC. (TLPH)United States$0.060B
Skye Bioscience, Inc. (SKYE)United States$0.061B-0.48
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Rein Therapeutics, Inc. (RNTX)United States$0.063B-1.76
HYPERION DEFI, INC. (HYPD)United States$0.065B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
XBiotech Inc. (XBIT)United States$0.066B-1.56
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Clene Inc. (CLNN)United States$0.054B-1.99